<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127957">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149875</url>
  </required_header>
  <id_info>
    <org_study_id>605872</org_study_id>
    <nct_id>NCT02149875</nct_id>
  </id_info>
  <brief_title>Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke</brief_title>
  <official_title>A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 6th People's Hospital</source>
  <oversight_info>
    <authority>China: Science and Technology Commission of Shanghai Municipality</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12
      hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a
      10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National
      Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the
      efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were
      also analyzed among the three groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS) score</measure>
    <time_frame>At 11-day and 21-day after therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scores range from 0 to 42, with higher scores indicating increasing severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>At 11-day and 21-day after therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Cerebral Stroke Within 12 Hours for the First Time</condition>
  <arm_group>
    <arm_group_label>Dl-3-n-butylphthalide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Dl-3-n-butylphthalide&quot;,  &quot;Cerebrolysin&quot; and &quot;Placebo&quot; separately</intervention_name>
    <arm_group_label>Dl-3-n-butylphthalide</arm_group_label>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke within 12 hours for the first time before entry into the study

          -  National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25

        Exclusion Criteria:

          -  with lacunar infarction

          -  with cerebral hemorrhagic infarction

          -  with epilepsy or epileptic persons

          -  with history of neurological diseases

          -  with myocardial infarction,

          -  with renal and hepatic abnormalities

          -  with metabolic diseases

          -  with contraindications to antiplatelet treatments
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University Affiliated Sixth People's Hospital</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 6th People's Hospital</investigator_affiliation>
    <investigator_full_name>Hao Chen</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Dl-3-n-butylphthalide</keyword>
  <keyword>Cerebrolysin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3-n-butylphthalide</mesh_term>
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
